TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway

Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancers and remains the most common cause of cancer-related death. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) have been used as first-line treatment for patients with NSCLC showing EGFR mutations...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Zhangxian, Li, Mingxi, Zhang, Xiaoqian, Rong, Xuezhu, Xu, Hongtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035062/
https://www.ncbi.nlm.nih.gov/pubmed/36896765
http://dx.doi.org/10.3892/or.2023.8521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035062/
https://www.ncbi.nlm.nih.gov/pubmed/36896765
http://dx.doi.org/10.3892/or.2023.8521

Ejemplares similares